Wu M-J, Kim M R, Chen Y-S, Yang J-Y, Chang C-J
Department of Basic Medical Sciences, Purdue University, West Lafayette, IN, USA.
Center for Cancer Research, Purdue University, West Lafayette, IN, USA.
Oncogene. 2017 Jun 1;36(22):3193-3206. doi: 10.1038/onc.2016.467. Epub 2017 Feb 20.
The key molecular mechanism governing the cancer cell state (stem cell-like state vs differentiation state) to control the cancer stem cell (CSC) pool remains elusive. This study provides the first evidence showing that all-trans retinoic acid (ATRA) induces the interaction and chromatin recruitment of a novel RARβ-TET2 complex to epigenetically activate a specific cohort of gene targets, including MiR-200c. TET2-activated miR-200c further targets and suppresses PKCζ, a cell polarity protein that has a pivotal role in directing asymmetric division of mammalian stem cells to sustain the stem cell pool. Our data reveal that pharmacological concentration of ATRA effectively downregulates PKCζ through activation of miR-200c, leading to a decrease of the stem cell-like populations from non-tumorigenic mammary epithelial cells and non-aggressive breast cancer cells. However, aggressive breast cancer cells that manifest TET2-miR-200c dysregulation sustain a CSC pool highly resistant to ATRA, where inhibition of PKCζ directs the resistant CSCs to the luminal cell-like state and sensitization to tamoxifen, resulting in abrogation of mammary tumor growth and progression. Together, these findings elucidate a novel RARβ-TET2-miR-200c-PKCζ signaling pathway that directs cancer cell state changes and also provide previously unidentified therapeutic implications for PKCζ inhibitors in diminishment of breast CSCs to eradicate breast cancer.
控制癌细胞状态(干细胞样状态与分化状态)以调控癌症干细胞(CSC)库的关键分子机制仍不清楚。本研究提供了首个证据,表明全反式维甲酸(ATRA)诱导一种新型RARβ-TET2复合物的相互作用和染色质募集,从而在表观遗传上激活包括MiR-200c在内的特定基因靶点群。TET2激活的MiR-200c进一步靶向并抑制PKCζ,PKCζ是一种细胞极性蛋白,在指导哺乳动物干细胞的不对称分裂以维持干细胞库方面具有关键作用。我们的数据显示,药理学浓度的ATRA通过激活MiR-200c有效下调PKCζ,导致非致瘤性乳腺上皮细胞和非侵袭性乳腺癌细胞中干细胞样群体减少。然而,表现出TET2-MiR-200c失调的侵袭性乳腺癌细胞维持着对ATRA高度耐药的CSC库,其中抑制PKCζ可将耐药CSC导向管腔样细胞状态并使其对他莫昔芬敏感,从而消除乳腺肿瘤的生长和进展。总之,这些发现阐明了一条指导癌细胞状态变化的新型RARβ-TET2-MiR-200c-PKCζ信号通路,也为PKCζ抑制剂在减少乳腺CSC以根除乳腺癌方面提供了此前未被发现的治疗意义。